Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
topiramate + phenytoin
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Topiramate and phenytoin are both antiepileptic (anticonvulsant) drugs used primarily for the management of seizure disorders. Topiramate is also indicated for migraine prophylaxis and, in combination with other agents, for chronic weight management. Topiramate acts by modulating voltage-dependent sodium channels, enhancing GABA-A receptor activity at non-benzodiazepine sites, inhibiting AMPA/kainate glutamate receptors, and weakly inhibiting carbonic anhydrase isozymes. Phenytoin primarily stabilizes neuronal membranes by promoting sodium efflux from neurons, thereby reducing excitability. When used together in patients with epilepsy, these drugs may have pharmacokinetic interactions but generally do not cause clinically significant changes at recommended doses[5]. Both drugs are small molecule anticonvulsants developed to control seizures; topiramate was discovered during research into antidiabetic agents but repurposed after its anticonvulsant properties were found[8].
- Brand names
- QsymiaQudexyTrokendi
- Other names
- topiramate, phenytoin
02
Targets
CA2 (Carbonic Anhydrase 2)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)AMPAR (AMPA receptor)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)NaV alpha (Voltage-gated sodium channel alpha subunit family)
Beyond the preview
Go deeper on topiramate + phenytoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on topiramate + phenytoin.